Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Reinnervate Partners with Oncotest and SBH Sciences

Published: Thursday, October 31, 2013
Last Updated: Thursday, October 31, 2013
Bookmark and Share
Companies to partner on introductory services for screening novel anti-cancer drugs using 3D tumour cell culture.

Reinnervate Ltd today announced partnerships with two oncology-focussed CRO‟s to offer 3D tumour cell screening services. The CROs, Oncotest GmbH (Freiburg, Germany) and SBH Sciences (Natick, MA, USA) will both offer a new service for clients wishing to try out cancer 3D cell culture screening for the first time or who wish to evaluate new tumour types in their models. 

The introductory service ranges in price from $1,499 to $2,499 and has the following experimental outline: 

• Client picks two cancer cell lines from the available panel (over 200 tumour cell lines are available)
• Client provides up to 2 test compounds or specifies two commercially available drugs to be used
• CROs include one positive control cell line and one positive control compound
• All 3 compounds are tested on the specified 3D tumour cells cultured in Alvetex® 96 3D cell culture plates
• A dose response experiment with ten concentrations in duplicates will be performed using the Promega Cell Titer-Glo® assay
• CRO provides a comprehensive data report with IC50 values and a follow-up telephone conference
• Comparison of 2D and 3D tumour cell responses can be provided (depending on service chosen) 

"These new introductory 3D tumour cell services will allow more scientists to explore the differences in drug response between 2D and 3D cultured tumour cells‟ said Richard Rowling, Commercial Director at Reinnervate Ltd. "These services have been priced at a level which should be affordable for most groups that have not yet had the time to explore the improved biological relevance offered by 3D cell culture systems‟ he added. 

Torsten Giesemann, Department Head at Oncotest commented, „We have been using Alvetex® 96 3D cell culture plates for some time now and are keen to help as many clients as possible explore the potential benefits of testing new oncology drugs on 3D tumour cells cultured in a 3D format. There is an increasing body of scientific data showing that tumour cells cultured as monolayers are a poor proxy for the in vivo situation.‟ 

SBH Sciences CEO, Raphael Nir said, „We have a panel of over 200 different tumour cell lines and look forward to helping our clients evaluate 3D tumour cell screening and compare the differences in drug response between 2D and 3D cell culture systems using Alvetex® technology‟.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
New Database for Sharing MS Clinical Trial Data
A new database containing nearly 2500 patient records from the placebo arms of nine multiple sclerosis (MS) clinical trials is now available for research by qualified investigators.
Study Finds Factors That May Influence Influenza Vaccine Effectiveness
Researchers at NIH have suggested that the long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited.
BMS’s Opdivo Clinical Trial Shows Promise
Safety profile of the combination regimen from CheckMate -069 was consistent with previously reported studies and adverse events were managed using established safety algorithms.
Treatment of Common Prostate Cancer
Researchers at UTSW have found that the prostate cancer treatments suppress immune response and may promote relapse.
Cancer Drug Could Treat Blood Vessel Deformities
A drug currently being trialled in cancer patients could also be used to treat an often incurable condition that can cause painful blood vessel overgrowths inside the skin.
Structure of Crucial Enzyme Identified
Researchers at UTSW have determined the atomic structure of an enzyme that plays an essential role in cell division and better treatment of cancer.
New Immunotherapy Trial for Type 1 Diabetes
The search for a treatment for Type 1 diabetes (T1D) - which affects over 400,000 people in the UK – will be stepped up with the start of a new phase one clinical trial at Guy’s Hospital in London.
Recruitment of First Patient in Clinical Study
Company has announced recruitment of first patient in clinical study assessing Visco-ease with Beatson Cancer Centre for the treatment of RIX.
Fighting Prostate Cancer
Identifying the most promising compounds which can be used as medications for prostate cancer.
Chi-Med Initiates Sulfatinib Phase III Registration Study
Company has initiated SANET-p, a Phase III registration trial of sulfatinib with pancreatic neuroendocrine tumors (“NETs”).
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!